In 2020, primary analysis of the pivotal phase 3 ADAURA trial demonstrated a substantial DFS benefit in patients with EGFR-mutated NSCLC who underwent complete tumor resection, with hazard ratios of 0.17 (99% CI 0.11 to 0.26; p < 0.001) for stage II to IIIA disease and 0.20 (99% CI 0.14 to 0.30; p < 0.001) for stage IB to IIIA disease compared to placebo. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.